Changes in Inflammatory Markers in Bacterial- and Nifedipine-Induced Gingival Inflammation

Anitha George¹, Sanil P George², Sajil John³, Nebu George⁴, Sheena Joe⁵, Riju Mathew⁶

Introduction

Inflammatory gingival enlargement is commonly observed in routine dental practice. Many drugs that induce gingival enlargement were reported in the literature. Anticonvulsants such as phenytoin, sodium valproate, phenobarbitone, vigabatrin, and carbamazepine; immunosuppressants like cyclosporine and calcium channel blockers like nifedipine, isradipine, felodipine, amlodipine, verapamil, and diltiazem are some among them.¹-³ The pathogenesis of gingival hyperplasia induced by drugs is still not completely understood even after extensive studies. Age, demographic variables, genetic factors, oral hygiene, etc., were implicated in gingival hyperplasia. These drugs are believed to cause cellular proliferation of gingiva by affecting the hormones like testosterone.⁴ The dose of the drug and the duration of therapy are correlating well with the degree of gingival hyperplasia. The incidence and degree of gingival hyperplasia increase with the concomitant use of drugs, although controversy still exists.³ Kataoka et al. had reported the direct effect of drugs like cyclosporine, phenytoin, and nifedipine on gingival cell activity.⁵ Cells growth enhancement and collagens protein production has been observed in cultures of human gingival cells directly stimulated with these drugs.²

Nifedipine used for treating the hypertension is one of the leading causes of the drug-induced gingival enlargement that was first reported three decades back² and still under investigation.⁶ Many factors like poor oral hygiene, high dose of the drugs, genetic factors, individual susceptibility, and drug its metabolites interaction with the fibroblasts of gingiva were attributed to the overgrowth of gingiva in nifedipine-induced hyperplasia.²⁷ In-depth mechanism of the process were studied by many investigators.¹

Porphyromonas gingivalis is periodontal pathogen reported to be present in the majority of subjects with periodontal diseases and scanty seen in subjects with good periodontal health. Evidence relating the pathogenic role of these bacteria is available in the literature; however, the molecular and physiological mechanism remains unexplained. The prevalence of coronary heart disease (CHD) is reported to be higher in patients with periodontitis. The role of the inflammatory markers, which predisposes an individual to CHD, was not investigated in any of these studies. Hence, in the present study, an attempt is being made to evaluate the impact of drug-induced and bacterial gingivitis on the inflammatory markers, which intern increase the risk of CHD.

Materials and Methods

Thirty-two patients with nifedipine-induced gingival enlargement, twelve with P. gingivalis infection, and seven with both drug and bacterial infection formed the test group and 16 age- and sex-matched healthy subjects formed the control. Gingival status was assessed, and the gingival index is noted. Fibrinogen and CRP were measured in venous blood. Results of the test and controls were compared using t-test and Pearson correlation.

Results

It was found that the changes in the inflammatory markers were statically significant in both fibrinogen levels and the CRP. The inflammation was more pronounced in subjects exposed to the drug and bacterial infection. The gingival index was found directly correlating with both the fibrinogen and the CRP levels.

Conclusion

The quantitative estimation of both fibrinogen and CRP are good markers for the quantification of inflammation and hence evaluating the risk of coronary heart disease (CHD). Substituting the drug and reducing the bacterial load will help in improving the outcome of the treatment and thereby reducing the risk of CHD.

Key Words: C-reactive protein, fibrinogen, gingivitis, gingival hyperplasia, gingival inflammation, nifedipine, Porphyromonas gingivalis
Fibrinogen is a protein synthesized by the liver and is intimately involved in blood clotting and inflammation management. It is a soluble protein, which gets converted into a solid fibrous protein that becomes the blood clot. Besides this, fibrinogen functions as a messenger molecule that coordinates and regulates our bodies’ response to inflammation. C-reactive protein (CRP) is an acute phase protein, the level of which will help to assess the degree of inflammation, and hence the risk of CHD. Our current study aims to correlate the effect of the drug-induced and bacterial gingivitis to the levels of the inflammatory markers.

Materials and Methods
Thirty-two patients with gingival enlargement due to nifedipine and twelve patients with gingival inflammation due to P. gingivalis infection and seven with P. gingivalis infection and nifedipine-induced gingival inflammation were identified by the physicians and referred to the dental clinic formed the test group. The diagnosis was confirmed by the dentist based on clinical assessment by comprehensive periodontal examination. The detailed examination consists of a visual examination, radiographs, probing of the gingiva to measure the extent of gingival damage and by laboratory investigation. P. gingivalis was identified by anaerobic culture technique. Gingival status was assessed based on tools of of Loe and Silness. Fibrinogen concentration was measured in heparinized plasma and CRP in serum by nephelometric method in BN ProSpec (Siemens) analyzer. The values were compared with 16 age and sex matched controls. The comparison is done using the one-way ANOVA test, and Pearson correlation is done using the SPSS 17 software and the minitab 15 software. A $P \leq 0.05$ was considered as statistically significant.

Result
The basic statistics of the study population is given in Table 1. The mean gingival index for the test population was 1.89 ± 0.74 for the gingivitis caused by drug, 2.14 ± 0.25 for gingivitis caused by bacteria and 3.81 ± 0.13 for gingivitis in subjects with drug and bacteria together (Graph 1 and Table 2), which shows that the inflammatory process was well-evident compared to the control population where the gingival index was 0.82 ± 0.11. The average fibrinogen level for the test population was elevated (drug [276.69 ± 10.15], bacterial [278.67 ± 27.14], and both [323 ± 13.56]) when compared to the control population who had a value of 204.3 ± 10.91 (Graph 2 and Table 2). Fibrinogen level in the test and the control population were statistically of high significance ($P < 0.001$). The CRP was elevated in test cases (drug [2.55 ± 0.58], bacterial [3.08 ± 0.57], and both [4.13 ± 0.81]) than the control population of 0.97 ± 0.24 which was also statistically highly significant (Graph 3 and Table 2). There is a positive correlation between fibrinogen and CRP levels. (Graph 2 and Table 2).

| Parameters | Mean±SD | Test population (n=51) | Control (n=16) |
|------------|---------|------------------------|---------------|
|            | Drug (n=32) | Bacterial (n=12) | Both (n=7) |            |
| Age        | 44.19±8.13 | 49±6.32 | 45.71±6.65 | 45.44±6.59 |
| Gingival index | 1.89±0.74 | 2.14±0.25 | 3.81±0.13 | 0.82±0.11 |
| Fibrinogen mg/dL | 276.69±10.15 | 278.67±27.14 | 323±13.56 | 204.25±10.91 |
| CRP mg/L   | 2.55±0.58 | 3.08±0.57 | 4.13±0.81 | 0.97±0.24 |

CRP: C-reactive protein, SD: Standard deviation
Inflammatory markers in bacterial- and drug-induced gingivitis 

George A et al

Journal of International Oral Health 2015; 7(Suppl 2):64-67

Correlation between the gingival index, the fibrinogen and CRP ($r = 0.803$ and $r = 0.808$, respectively) (Table 3 and Graph 4).

**Discussion**

Epithelial cellular invasion by pathogenic bacteria is well-documented. $^9$ Nifedipine causes cellular enlargement by altering hormones like testosterone. When both the causes are present in the same individual, the degree of inflammation is expected to be to be more. It was observed in our study that the gingivial inflammation in nifedipine-induced gingivitis and bacterial infection significantly elevated the fibrosis of the gingiva and is evidenced by the significant elevation in the blood levels of fibrinogen and CRP. Similar observation were reported by Trackman et al.$^2$ and Taylor, et al. in drug-induced gingivitis.$^{10}$ We have observed elevated levels of inflammatory markers in gingivitis-induced either by the drug or by the bacteria.

The elevation in markers was more pronounced when both the causes were present concurrently. It may be due to the fact that a bacterial infection can cause inflammation, and this may further aggravate the inflammation induced by nifedipine. Studies on the concurrent effect of drug- and bacterial-induced inflammation are scanty, and no such reports are available on the levels of the inflammatory markers and gingivitis. A case-control study with more subjects will help in elucidating the mechanism of inflammation in such subjects.

Even though many etiological factors are attributed to the high prevalence of CHD, reports available on the role of gingivitis or other inflammatory periodontal conditions predisposing an individual to CHD are scanty. In these cases, the risk can be evaluated by measuring the inflammatory markers such as fibrinogen, CRP, etc., in circulation. Once these markers are found to be elevated, the risk of CHD can be reduced by substituting nifedipine and treating for bacterial infection.$^{11,12}$ From our study, it was observed that the level of fibrinogen and CRP may also serve as a marker for gingivitis. Since there is a strong established correlation of elevated fibrinogen and CRP to the cardiovascular disease regular estimation of the fibrinogen and CRP will help in monitoring the patients so that preventive measures can be initiated, thereby the prevalence CHD can be reduced.$^{13}$

**Conclusion**

The quantitative estimation of both fibrinogen and CRP are good markers of nifedipine-induced gingival enlargement. Due to the direct positive correlation between the gingival index and the markers, these markers can be used to evaluate the extent of gingival inflammation caused by the drugs. The study emphasizes the need for regular assessment of drug-induced gingivitis as the raised inflammatory markers are measurands of coronary artery disease.
References

1. Kataoka M, Kido J, Shinohara Y, Nagata T. Drug-induced gingival overgrowth: A review. Biol Pharm Bull 2005;28(10):1817-21.
2. PC, Kantarci A. Molecular and clinical aspects of drug-induced gingival overgrowth. J Dent Res 2015;94(4):540-6.
3. Dongari-Bagtzoglou A, Research, Science and Therapy Committee, American Academy of Periodontology. Drug-associated gingival enlargement. J Periodontol 2004;75(10):1424-31.
4. Mariotti A, Mawhinney M. Endocrinology of sex steroid hormones and cell dynamics in the periodontium. Periodontol 2000 2013;61(1):69-88.
5. Ellis JS, Monkman SC, Seymour RA, Idle JR. Determination of nifedipine in gingival crevicular fluid: a capillary gas chromatographic method for nifedipine in microlitre volumes of biological fluid. J Chromatogr 1993;621(1):95-101.
6. Straka M, Varga I, Erdelšky I, Straka-Trapezanlidis M, Krnovová J. Drug-induced gingival enlargement. Neuro Endocrinol Lett 2014;35:567-76.
7. Eslami M, Baghali F, Jalayer Nadery N. An investigation on gingival hyperplasia induced by nifedipine. J Dent (Tehran) 2004;1(1):33-7.
8. Loe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963;21:533-51.
9. Lamont RJ, Alex C, Belton CM, Izutsu KT, Vasel D, Weinberg A. Porphyromonas gingivalis invasion of gingival epithelial cells. Infection Immun 1995;63(10):3878-85.
10. Taylor JE, Belch JJ, McLaren M, Stewart WK. Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin. Blood Coagul Fibrinolysis 1995;6(2):100-4.
11. Itam SN, Jyoti RR. Effect of periodontal treatment on plasma fibrinogen, serum C-reactive protein and total white blood cell count in periodontitis patients: A prospective interventional trial. Rom J Intern Med 2013;51(1):45-51.
12. Almaghlouth AA, Cionca N, Cancela JA, Décaillot F, Courvoisier DS, Giannopoulou C, et al. Effect of periodontal treatment on peak serum levels of inflammatory markers. Clin Oral Investig 2014;18(9):2113-21.
13. Toliya AV, Patel V, Panchal A, Mehta H, Nanavati B. Periodontitis and cardiovascular disease-A much discussed relationship. Natl J Integr Res Med 2014;5(1):134-8.